Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06491563 | Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | PHASE2 | ACTIVE NOT_RECRUITING | 150 | — | — | Aug 6, 2024 | Jun 1, 2027 | Dec 30, 2024 | 12 | China |
| Arm | Type | Description |
|---|---|---|
| BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα | EXPERIMENTAL | Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy. |
| BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα | EXPERIMENTAL | Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy. |
| Name | Type | Description |
|---|---|---|
| BRII-179 | BIOLOGICAL | BRII-179 will be given via intramuscular injection |
| BRII-835 (VIR-2218) | DRUG | BRII-835 will be given via subcutaneous injection |
| PEG-IFNα | BIOLOGICAL | PEG-IFNα will be given via subcutaneous injection |
Inclusion Criteria: * 1\. Male or female aged 18-60 years. * 2\. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2. * 3\. Chronic HBV infection for ≥ 6 months. * 4\. On NRTI therapy for ≥ 6 months. Exclusion Criteria: * 1\. Any clinically significant chronic or acute medical condition that makes the part...